HRR testing: Best-practice sample collection
As genetic testing becomes routine in mPC, ensuring highquality samples is essential for producing accurate, actionable results. Anders Bjartell (Lund University and Skåne University Hospital in Malmö, Sweden) highlights how timing, tumor content, and coordinated workflows impact realworld HRR and circulating tumor DNA (ctDNA) testing. View video. View transcript.
Developed by EPG Health. This content has been developed independently of the sponsor, Pfizer, which has had no editorial input into the content. EPG Health received funding from the sponsor to help provide healthcare professional members with access to the highest quality medical and scientific information, education and associated relevant content. This content is intended for healthcare professionals only.